Sondak, Vernon K.

Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma

Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 919

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma

Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., et al. (2008) · Journal of Clinical Oncology

Microbial Inactivation MethodsImmunotherapy and Immune Responses

Cited by 701

12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

Messina, J. L., Fenstermacher, D. A., Eschrich, S., Qu, X., Berglund, A. E., Lloyd, M. C., Schell, M. J., Sondak, V. K., Weber, J. S., & Mulé, J. J. (2012) · Scientific Reports

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 426

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

Paraiso, K. H. T., Fedorenko, I. V., Cantini, L. P., Munko, A. C., Hall, M., Sondak, V. K., Messina, J. L., Flaherty, K. T., & Smalley, K. S. M. (2010) · British Journal of Cancer

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 314

Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609

Tarhini, A. A., Lee, S. J., Hodi, F. S., Rao, U. N. M., Cohen, G. I., Hamid, O., Hutchins, L. F., Sosman, J. A., Kluger, H. M., Eroglu, Z., et al. (2020) · Journal of Clinical Oncology

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 184

HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy

Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research

Melanoma and MAPK PathwaysHistone Deacetylase Inhibitors Research

Cited by 73

Inhibition of autophagy enhances the effects of the AKT inhibitor MK‐2206 when combined with paclitaxel and carboplatin in BRAF wild‐type melanoma

Rebecca, V. W., Massaro, R. R., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., Kim, E., Amaravadi, R. K., Maria‐Engler, S. S., Messina, J. L., Gibney, G. T., et al. (2014) · Pigment Cell & Melanoma Research

Melanoma and MAPK PathwaysAutophagy in Disease and Therapy

Cited by 58

Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy

Reinstein, Z. Z., Zhang, Y., Ospina, O. E., Nichols, M. D., Chu, V. A., Pulido, A. D. M., Prieto, K., Nguyen, J. V., Yin, R., Moran Segura, C., et al. (2024) · Cancer Discovery

Polyomavirus and related diseasesCancer Immunotherapy and Biomarkers

Cited by 33